Clinical Studies

clic on a specific trial for more informations

Dementia

Alzheimer’s disease

  • Skyline (sponsor: Roche): anti-amyloid antibody; bi-monthly subcutaneous injection of Gantenerumab in asymptomatic adults older than 60 with evidence of amyloidosis after blood test and PET scanning. PI: Pr Bernard Hanseeuw. Starting date: Summer 2022. https://clinicaltrials.gov/ct2/show/NCT05256134
  • A Study to Test the Efficacy, Safety, and Tolerability of Bepranemab (UCB0107) in Patients With Mild Cognitive Impairment or Mild Alzheimer’s Disease (AD) (NCT04867616) (PI: Rik Vandenberghe, UZ Leuven)
  • A Study of JNJ-63733657 in Participants With Early Alzheimer’s Disease (Autonomy)(NCT04619420) (PI: Rik Vandenberghe, UZ Leuven)
  • A Research Study Investigating Semaglutide in People With early Alzheimer’s Disease (EVOKE Plus) (NCT04777409) (PI: Rik Vandenberghe, UZ Leuven)

    Frontotemporal degeneration:

    • Phase 1/2 Clinical Trial of PR006 in Patients With Frontotemporal Dementia with Progranulin Mutations (FTD-GRN) (PROCLAIM) (NCT04408625) (PI: Rik Vandenberghe, UZ Leuven)
    • A Phase 3 Study to Evaluate Efficacy and Safety of AL001 in Frontotemporal Dementia (INFRONT-3) (NCT04374136) (PI: Rik Vandenberghe, UZ Leuven)
    • Study of WVE-004 in Patients With C9orf72-associated Amyotrophic Lateral Sclerosis (ALS) or Frontotemporal Dementia (FTD) (FOCUS-C9) (NCT04931862) (PI: Rik Vandenberghe en Philip Van Damme, UZ Leuven)
    • Fahr’s disease:

     Neuromuscular Disease:

    Pompe’s disease:

    Limb-girdle muscle dystrophy (LGMD):

     

    Mitochondrial myopathy:

     

    transthyretine (TTR) polyneuropathy:

     

    Charcot-Marie-Tooth neuropathy (CMT):

     

    Chronic Inflammatory Demyelinating Polyneuropathy (CIDP):

     

    Myasthenia gravis:

    Inflammatoire myopathieën/Myositis:

      Spinale Musculaire Atropfie (SMA):

      Fibrodysplasia ossificans progressiva (FOP):

      Amyotrophic lateral sclerosis (ALS):

      Epilepsie:

      • Multimodal profiling of people with epilepsy to determine which signals are clinically useful for long-term home monitoring (NCT04642105) (PI: Wim Van Paesschen, UZ Leuven)
      • Marinus, Refractory status epilepticus A double-blind, randomized, placebo-controlled study to evaluate the efficacy, safety, and tolerability of intravenous ganaxolone added to standard of care in refractory status epilepticus Ganaxolone 3 2022-502540-12

      SHARE YOUR TRIAL WITH US

      Please complete the required fields.

       

      Belgian Neurological Society

      Society address :

      Domeindreef 10

      8200 Sint Michiels

      0499/925.788

      BNS secretary : 

      ✉︎  bns@neuro.be